Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 7

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 7
---
Except as otherwise indicated, all information
in this prospectus assumes that:

| ● | no shares of common stock                                                                                      
 have been issued pursuant to any warrants or options, including the Warrants and the Placement Agent Warrants. |

<div align='center'>TRADEMARKS</div>

Solely for convenience, our trademarks and tradenames
referred to in this prospectus, may appear without the ® or ™ symbols, but such references are not intended to indicate in any
way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other trademarks,
service marks and trade names included or incorporated by reference into this prospectus or the accompanying prospectus are the property
of their respective owners.

<div align='center'>GLOSSARY OF SELECTED TERMS</div>

The following are definitions of certain terms
that are commonly used in the medical industry and in this prospectus:

| ● | “API” means active pharmaceutical ingredient, the      
 active molecule contained in a pharmaceutical product. |

| ● | “Arakoda” means ARAKODA®, the 60P-owned                                                                                                  
 and FDA-approved product to prevent malaria in travelers, which contains as its active pharmaceutical ingredient, Tafenoquine succinate. |

| ● | “Broad Spectrum of Activity” refers to a molecule              
 or drug that is active against a range of different pathogens. |

<div align='center'>ii</div>

| ● | “Dengue” means a mosquito-borne viral disease occurring 
 in tropical and subtropical areas.                      |

| ● | “EUA” means Emergency Use Authorization. |

| ● | “FDA” refers to the U.S. Food and Drug Administration. |

| ● | “G6PD” means glucose-6-phosphate dehydrogenase. |

| ● | “Kodatef” is the brand name of Arakoda outside the                                                     
 United States. Kodatef has been approved for use in Australia by the Therapeutic Goods Administration. |

| ● | “Legacy Studies” is a reference to the collection                                                                                        
 of clinical and non-clinical studies involving Tafenoquine, which were conducted by the U.S. Army prior to 2014, and which were included 
 in the new drug application submitted by 60P to the FDA in 2018. Some of those Legacy Studies are described in the account of the Army   
 development program published by Zottig et. al.                                                                                          |